Roslin Cell Therapies Ltd was formed, following the creation of Roslin Cells Ltd, to focus on the delivery of GMP contract manufacturing services. Roslin Cell Therapies Ltd continues to trade under the trade name RoslinCT.

Building on this wealth of scientific expertise, Roslin Cells Ltd was formed as a spin-out from the Roslin Institute in 2006.

Roslin Cells Ltd built on the legacy of Dolly and aimed to advance the field of regenerative medicine by providing human embryonic stem cell (hESC) derivation services. By 2009, Roslin Cells Ltd had positioned itself as a pioneer in hESC derivation, differentiation and characterisation and became the first European company to successfully establish a GMP grade hESC line.

Roslin Cells Ltd also aided in the establishment of the first European Bank for induced pluripotent Stem Cells (EBiSC). The EbiSC collaboration was designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research-grade iPSC lines, data and cell services.

In 2015, in order to focus exclusively on the delivery of its GMP contract manufacturing services, Roslin Cell Therapies Ltd was formed. Roslin Cell Therapies Ltd continues to trade under the trade name RoslinCT.

Today, more than a decade after our journey began, RoslinCT is an established leader and a reliable partner for the development, optimization, scale-up and GMP manufacture of cell-based therapeutic products. We show commitment to working to the highest quality standards and provide reliable yet flexible and accommodating expert services to accelerate the route to market for our clients.

Roslin CT Timeline

2006

Spin Out Created

Roslin Cells Ltd. spun out from the Roslin Institute to produce clinical-grade human embryonic stem cell lines. Not-for-profit company (Roslin Foundation and The University of Edinburgh as founders, financial support by Scottish Enterprise).

2008

First GMP hESCs

Roslin Cells Ltd focuses on derivation and characterisation of hESC and becomes the first European company to generate a GMP hESC line.

2009

HTA Approval

Roslin Cells Ltd obtains Human Tissue Authority (HTA) Licence awarded for the procurement, import, processing, and testing of human cells and tissues.

2012

Moving to SCRM

Moved to the Scottish Centre for Regenerative Medicine, a custom-built ATMP manufacturing facility.

2013

MHRA Licence obtained

Roslin Cell Ltd completes the build and validation of the GMP Manufacturing Facility at SCRM and obtains appropriate MIA (IMP) from the MHRA for the production of ATMP's.

2015

Focus on CDMO business

Roslin Cell Therapies Ltd formed to focus on GMP contract manufacturing services.

2017

Launch of the RoslinCT Brand

RoslinCT brand launched with a focus on CDMO activities – fully commercial business

2021

Expansion of our manufacturing capacity

Expansion to our new manufacturing centre. The new state of the art 1,600 m2 facility will operate to US and EU GMP standards and will become an innovative hub for the manufacture of cell and gene therapy products.

Search